ESBATech

About:

ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.

Website: http://www.esbatech.com

Top Investors: SV Health Investors, Novartis Venture Fund, VI Partners, HBM Healthcare Investments, Clarus Ventures

Description:

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.